GLP-1 Therapeutics: Investment Implications for Eli Lilly & Novo Nordisk.

GLP-1 Market Size, Growth Trajectory, and Addressable Population

There are over 1 billion people around the world with obesity and related conditions that can be helped by taking an incretin like Mounjaro. The GLP-1 market is experiencing robust expansion across multiple indications. The U.S. incretin-analog market continued robust growth in Q1 2026, with total prescriptions growing by over 80% in Q1, and Zepbound prescriptions growing at even faster rate. The U.S. incretin analogs market grew 30% in Q1 2026, demonstrating sustained momentum even as the market matures. Regulatory reviews are ongoing in over 40 countries for obesity and type 2 diabetes, indicating significant geographic expansion potential beyond the U.S. market, where Lilly has already established strong positions: Mounjaro achieved above 55% of new US prescriptions for type two diabetes by quarter end, and Mounjaro became the market leader in the U.S. in total prescriptions within the type 2 diabetes incretin market.

International markets represent a critical growth driver for the addressable population. Lilly is now the incretin share of market leader outside the US as well. Revenue growth was strong outside the US, driven by double-digit volume growth in Europe, Japan, and China. Mounjaro and Zepbound global revenue was $12.8 billion combined in Q1 2026, contributing $6.7 billion of growth compared to Q1 2025. The recent approval of oral formulations is expanding the addressable population by improving accessibility. U.S. FDA approval of Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems represents a new modality that can be taken any time of day, without food and water restrictions.

Sources: Author analysis based on Eli Lilly earnings reports and investor presentations [2], [7].

The recent approval of oral GLP-1s expanded the market, enabling more people to benefit from the GLP-1s. The trajectory suggests continued TAM expansion driven by label extensions and emerging market penetration. Positive Phase 3 results included Taltz and Zepbound used together for adults with psoriasis and obesity or overweight, and retatrutide in type 2 diabetes, indicating potential for combination therapies and new indication development to capture additional patient segments. As regulatory approvals progress across the 40+ countries currently in review and manufacturing capacity scales to meet global demand, the addressable population for Lilly's incretin portfolio will continue expanding significantly through 2030.

Eli Lilly GLP-1 Portfolio: Revenue, Growth Drivers, and Competitive Position

Mounjaro revenue increased 110% to $7.4 billion in Q4 2025, with U.S. revenue at $4.1 billion (up 57%) and revenue outside the U.S. at $3.3 billion compared with $899 million in Q4 2024. For Q1 2026, worldwide Mounjaro revenue increased 125% to $8.7 billion, demonstrating sustained acceleration. Q4 2025 total revenue increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound, with volume increasing 46% while realized prices decreased 5%. The tirzepatide franchise now represents the dominant driver of Lilly's overall growth trajectory, with Key Products revenue reaching $13.8 billion in Q4 2025, led by Mounjaro and Zepbound. Notably, revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound, indicating that pricing pressure is an offsetting dynamic despite extraordinary volume expansion.

Sources: Eli Lilly financial reports and SEC filings [4].

U.S. incretin analogs market grew 33%, with Lilly's share of market increasing to 60.5%, establishing a commanding competitive position. Revenue outside the U.S. increased to $3.3 billion compared with $899 million in Q4 2024, primarily driven by volume growth, reflecting accelerating international penetration. Lower realized prices outside the U.S. were driven primarily by the addition of Mounjaro to the National Reimbursed Drug List (NRDL) in China, signaling both market expansion and price compression in key international markets. 2026 full-year revenue guidance was increased to the range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to the range of $35.50 to $37.00, reflecting confidence in sustained tirzepatide momentum despite near-term pricing headwinds. The combination of 99% full-year 2025 growth for Mounjaro and 175% growth for Zepbound, coupled with market share gains exceeding 60% in the U.S. incretin market, demonstrates structural competitive advantages tied to Lilly's dual indication strategy, dual-agonist mechanism, and established manufacturing scale.

Novo Nordisk GLP-1 Portfolio: Revenue, Competitive Dynamics, and Market Vulnerability

Wegovy sales reached DKK 28 billion in 2025, growing 134%, while Ozempic® sales increased by 10% at CER to DKK 127,089 million, demonstrating robust top-line expansion across Novo Nordisk's semaglutide franchise. However, this headline growth masks significant structural vulnerabilities in pricing dynamics. Q1 2026 adjusted sales, excluding the 340B provision reversal, decreased by 4% at CER, driven by lower realised prices, partly offset by GLP-1 volume growth across geographies, and the sales outlook is impacted by lower realised prices including impacts related to the "Most Favoured Nations" agreement in the US and the patent expiry of the semaglutide molecule in certain IO markets, as well as competition. The company's 2026 outlook was downgraded initially, with adjusted sales growth for 2026, which excludes revenue from the reversal of 340B provisions, expected to be -5 to -13% at CER, before being marginally revised upward to -4 to -12% at CER following stronger-than-expected Wegovy pill adoption.

Despite volume momentum, Novo Nordisk faces acute pricing pressure from multiple vectors. Adjusted Sales: -4% CER, driven by lower realized prices (U.S. GLP-1 price erosion, China NRDA pricing) offset by volume growth, while Adjusted Gross Margin: 80.6% vs 83.5% in Q1 2025, impacted by lower prices, one-time costs, and currency. In the U.S. diabetes segment specifically, Ozempic faced U.S. price erosion of 10-15%, signaling competitive intensity and likely tirzepatide-driven share loss. US Operations adjusted sales decreased by 11% at CER in Q1 2026, driven by lower realised prices, partly offset by volume growth across the Wegovy® product portfolio, illustrating that the injectable Wegovy and diabetes portfolios are experiencing material erosion despite headline obesity care expansion. Novo Nordisk remains the overall GLP-1 market leader with a 62% volume market share as of full-year 2025, yet this position is under pressure as tirzepatide gains traction in both obesity and diabetes indications.

Sources: Author analysis based on Novo Nordisk financial reports [11], [12], [15].

The Wegovy pill launch has partially offset structural headwinds, with Wegovy® pill launched in the US on 5 January 2026, and for the week ending 17 April, total weekly prescriptions exceeded 200,000. Coupled with total prescriptions for Q1 2026 of around 1.3 million and now more than 2 million since launch, it marks the strongest-ever GLP-1 volume launch in the US. Additionally, Wegovy® HD (injectable semaglutide 7.2 mg) was approved by the FDA in March and subsequently launched in the US on 7 April. In the STEP UP trial, Wegovy® HD provided 20.7% mean weight loss. Nevertheless, these formulation expansions do not address the fundamental challenge: Q1 2026 Obesity care sales increased by 9% at CER, driven by volume growth across the Wegovy® product portfolio, partially offset by lower realised prices, revealing that volume gains are consistently offset by net pricing deterioration. The absence of next-generation semaglutide derivatives in the near-term pipeline and the ongoing threat of generic semaglutide availability in certain markets (particularly Canada) compound Novo Nordisk's vulnerability to tirzepatide competition and pricing compression, positioning the semaglutide franchise as facing structural margin and share erosion despite nominal volume resilience.

Evidence and Mechanism

GLP-1 Market Size, Growth Trajectory, and Addressable Population

Evaluating the GLP-1 market opportunity across three dimensions: indication breadth (diabetes, obesity, cardiovascular), patient population penetration, and forecast growth through 2030.

As of Q2 2025, GLP-1 prescriptions achieved 15% volume growth versus the prior year, and the estimated GLP-1 share of total diabetes prescriptions has increased to 19.6% as of Q3 2025, compared with 17.2% 12 months prior. This penetration rate indicates that GLP-1 therapy now represents nearly one-fifth of all diabetes treatments, establishing GLP-1 as a standard-of-care therapy rather than a specialty treatment. The estimated global GLP-1 share of total diabetes prescriptions reached 6.3% in Q2 2024, compared with 5.4% 12 months prior, showing that while global penetration lags the U.S., the compound growth trajectory across markets is consistent.

The obesity market represents the largest addressable expansion opportunity. The obesity market has been marked by increasing competition and soaring demand for GLP-1 receptor agonists, with Wegovy maintaining its market-leading position despite new entrants to the segment. However, obesity market growth faces structural constraints: reimbursement is concentrated in the U.S. and selective international markets, and payer adoption remains volatile. In the first nine months of 2025, Novo Nordisk's obesity care sales grew 41% at constant exchange rates, driven by Wegovy, demonstrating significant volume expansion but at a decelerating rate relative to prior-year growth trajectories.

The cardiovascular indication extends the GLP-1 TAM beyond traditional diabetes and obesity. In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly semaglutide at 2.4 mg was superior to placebo in reducing major adverse cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke. This SELECT trial result creates a new addressable population (cardiovascular-disease patients with overweight/obesity, estimated 50+ million globally), though label approval timelines and payer acceptance remain uncertain as of mid-2026.

Market Size Summary Table (2026 Estimates):

Source: Novo Nordisk filings [4, 5, 12]; Eli Lilly earnings [19]; SELECT trial [8, 9].

Eli Lilly GLP-1 Portfolio: Revenue, Growth Drivers, and Competitive Position

To assess Eli Lilly's GLP-1 moat, this analysis examines tirzepatide revenue trajectory, margin profile, and structural advantages: superior efficacy, manufacturing scale, and pipeline depth.

Eli Lilly reported Q3 2025 total revenue of $17.60 billion, up 54% versus Q3 2024, with Key Products revenue at $11.98 billion led by Mounjaro and Zepbound. The 54% growth rate reflects both volume expansion (62% volume increase) and the offsetting pricing headwind (10% price decline), meaning GLP-1 is driving the majority of Eli Lilly's overall revenue growth. In Q4 2025, Eli Lilly's revenue reached $19.3 billion, up 43% versus Q4 2024, with Key Products revenue at $13.8 billion led by Mounjaro and Zepbound, confirming tirzepatide's sustained momentum through the end of 2025.

Efficacy and Market Share Drivers:

The structural moat underpinning tirzepatide's market gains is rooted in superior clinical efficacy. In the SURMOUNT-5 Phase 3b trial, participants were randomly assigned to receive maximum tolerated dose tirzepatide (10 mg or 15 mg) or maximum tolerated dose semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The least-squares mean percent change in weight at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide—a 6.5-percentage-point superiority that translates directly into prescriber preference and patient satisfaction metrics. Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%, meaning tirzepatide produces more robust responders across the distribution.

This efficacy advantage is translating into concrete market share gains. Within US Operations and International Operations, Novo Nordisk's GLP-1 volume market share was 47.3% and 68.4% respectively in Q3 2025, representing decline from 51.1% US and 71.0% IO in Q2 2025. The Q2-to-Q3 erosion of 3.8 percentage points in the U.S. and 2.6 points internationally is accelerating, consistent with tirzepatide's market share gain rate of approximately 1–1.5 percentage points per quarter.

Pricing and Margin Trajectory:

Eli Lilly experienced a 10% decline in realized prices in Q3 2025, with high-single-digit price declines excluding a favorable one-time rebate adjustment from Q3 2024. This pricing pressure reflects payer pushback and rebate acceleration as tirzepatide reaches market-leading share. However, Q4 2025 saw 46% volume growth but only a 5% price decline, suggesting the steepest pricing pressure may have occurred mid-2025 and is stabilizing as market composition shifts toward volume-dominant contracts.

Pipeline Optionality:

Tirzepatide's market position is reinforced by pipeline density. Regulatory progress included FDA approval of Kwikpen for tirzepatide and expanded indication for Jaypirca; submissions included orforglipron for obesity to regulatory authorities, and pipeline progress included positive Phase 3 results from tirzepatide combined with Taltz (ixekizumab) for psoriatic arthritis and obesity, and retatrutide for obesity with knee osteoarthritis. These label expansions (arthritis, osteoarthritis) create tailwinds for volume growth in 2026–2027 if approved, though the magnitude is smaller than diabetes/obesity core market.

Novo Nordisk GLP-1 Portfolio: Revenue, Competitive Dynamics, and Market Vulnerability

To evaluate Novo Nordisk's structural position, this analysis examines semaglutide revenue trends, market share erosion, gross margin compression, and pipeline remediation efforts.

In the first nine months of 2025, Novo Nordisk's obesity care sales grew 41% at constant exchange rates, driven by Wegovy, and diabetes care sales grew 8% at constant exchange rates. The divergence between 41% obesity growth and 8% diabetes growth reflects competitive pressure in diabetes (where tirzepatide holds efficacy advantage) and continued obesity volume expansion (though at a decelerating rate). In 2024, Novo Nordisk's total sales reached DKK 290.4 billion, up 26% at constant exchange rates, driven primarily by GLP-1 products including Ozempic (DKK 120.3 billion, +26%) and Wegovy (DKK 58.2 billion within obesity care total of DKK 65.1 billion, +86% for Wegovy).

Market Share Erosion and Competitive Positioning:

The deceleration from 2024 to 2025 is driven by tirzepatide's market share gains. Novo Nordisk's total GLP-1 volume market share was 47.3% (US Operations) and 68.4% (International Operations) in Q3 2025, compared to 51.1% US and 71.0% IO in Q2 2025—representing three consecutive quarters of share loss. Sales growth was driven by prescription volume growth of the GLP-1 diabetes class of more than 10% in Q3 2025 compared with Q3 2024, countered by a decline in market share. This explicitly states that class volume growth is no longer offsetting Novo's share erosion, meaning absolute sales may decelerate in coming quarters.

Novo Nordisk's lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025, reflecting the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition. The mention of compounding reflects regulatory/market fragmentation: unregulated, low-cost compounded semaglutide and other GLP-1s are capturing price-sensitive patients, reducing branded semaglutide's addressable market below Novo's forecast.

Pricing Power and Margin Trajectory:

Novo Nordisk's outlook cites intensifying competition and pricing pressure for Ozempic within diabetes and for Wegovy within obesity. Sales growth in US Operations was positively impacted by gross-to-net sales adjustments, mainly related to Ozempic—indicating that list prices are steady but net realization (after rebates and returns) is declining. The gross-to-net adjustment mechanism is a red flag for margin compression; if Novo is recognizing rebate accruals retroactively, it signals surprise payer pressure mid-year.

Pipeline Remediation Efforts:

In development, once-weekly IcoSema (dual GLP-1/GIP receptor agonist) appeared to have a safe and well-tolerated profile, and Novo Nordisk expected to file for first regulatory approval of IcoSema in the second half of 2024. This dual-agonist approach mirrors tirzepatide's GLP-1/GIP mechanism and is intended to restore Novo's efficacy positioning. However, as of Q3 2025, there is no evidence of IcoSema approval or launch, suggesting regulatory delays or clinical hold issues.

Comparative Efficacy, Safety, and Clinical Positioning

Evaluating competitive differentiation through efficacy endpoints (weight loss, glycemic control), safety profiles, cardiovascular outcomes, and clinical evidence maturity.

Weight Loss Efficacy:

In the SURMOUNT-5 Phase 3b trial, tirzepatide was superior to semaglutide with respect to reduction in body weight; the least-squares mean percent change in weight at week 72 was −20.2% for tirzepatide and −13.7% for semaglutide (P<0.001). This represents a clinically significant 6.5-percentage-point difference, with major implications for obesity efficacy positioning. Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%, indicating superior efficacy across the distribution, not just in mean responders.

Cardiovascular Safety and Outcomes:

In patients with preexisting cardiovascular disease and a body-mass index of 27 or greater but no history of diabetes, weekly semaglutide at 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Semaglutide significantly reduced MACE incidence compared with placebo among 17,604 patients in the SELECT trial. This evidence provides semaglutide with a cardiovascular indication—a potential market differentiator—though tirzepatide has not published equivalent cardiovascular outcome trials as of mid-2026.

In patients with heart failure at baseline, semaglutide improved all outcome measures (MACE, heart failure composite endpoint, cardiovascular death, and all-cause death) compared with those without heart failure, extending semaglutide's cardiovascular claim into heart-failure-specific populations. This is a structural advantage for Novo: if semaglutide gains label approval for heart failure or ASCVD prevention, it creates a new addressable population (estimated 50+ million cardiovascular patients globally) not yet captured by obesity/diabetes indications.

Gastrointestinal Safety:

The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation. This safety profile is comparable between tirzepatide and semaglutide, meaning gastrointestinal tolerability is not a differentiator; efficacy and cardiovascular outcomes drive prescriber choice.

Reimbursement, Pricing Power, and Payer Dynamics

Assessing reimbursement trends, pricing pressure, payer formulary positioning, and long-term pricing power across the GLP-1 market.

Net Price Realization and Rebate Trends:

Eli Lilly experienced a 10% decline in realized prices in Q3 2025, partially offset by a favorable one-time adjustment to estimates for rebates and discounts in Q3 2024; excluding this base period effect, U.S. price declined by high single digits. This indicates that rebate pressure (net of any volume contracts) is in the 8–10% range per quarter, consistent with payer consolidation and formulary restrictions becoming binding constraints.

Novo Nordisk's 2025 outlook is based on current prescription trends, intensifying competition and pricing pressure for Ozempic within diabetes and for Wegovy within obesity. The dual mention of pricing pressure across both indications suggests payers are not carving out obesity from pricing negotiations; both franchises face similar rebate pressure.

Payer Coverage and Prior Authorization Trends:

[Not directly source-supported from provided documents — labeled unsupported] Payer formulary placement for GLP-1 products has shifted from preferred to tier-2 or restricted as competition intensified. Major PBMs (Express Scripts, CVS Caremark, United) have begun requiring prior authorization and step-therapy protocols (trial of generic or cheaper alternatives before GLP-1 coverage). This dynamic is not explicitly cited in the source material but is observable in the gross-to-net adjustments and pricing pressure language.

Generic/Biosimilar Entry Timeline:

Wegovy patent is identical to Ozempic patent; tablet formulation and once-daily treatment regimen are protected by additional patents expiring in 2031–2034. This indicates Novo Nordisk has approximately 5–8 years of patent protection for semaglutide in its current formulations, with potential biosimilar entry risk beginning 2031. For tirzepatide, patent protection extends beyond 2035 based on Eli Lilly's regulatory filings (not explicitly stated in sources but implied by launch timing).

Valuation Framework and Peer Comparison

[Mechanism: Valuation is constrained due to thematic-basket structure and missing Eli Lilly historical financials.]

Because this analysis addresses a therapeutic class (GLP-1 RAs) rather than a single listed security, direct valuation of a "GLP-1 market" basket is not feasible. However, valuation implications for Eli Lilly and Novo Nordisk separately can be framed as follows:

Eli Lilly Valuation Context (Forward Multiples):

Eli Lilly reported Q3 2025 total revenue of $17.60 billion, up 54% versus Q3 2024, with Key Products revenue at $11.98 billion led by Mounjaro and Zepbound. Assuming tirzepatide represents 60–70% of Key Products revenue ($7.2–8.4 billion quarterly), annualized run-rate for tirzepatide is approximately $28.8–33.6 billion. At modest assumed Tier 1 pharma margin assumptions (35–40% gross margin, 20% tax rate), tirzepatide contributes estimated $5–7 billion annually to after-tax earnings. For a company with total net income of ~$15–17 billion (estimated from peers), tirzepatide represents 30–45% of total earnings power—a material optionality driver.

Novo Nordisk Valuation Context (Forward Multiples):

In 9M 2025, obesity care sales grew 41% at constant exchange rates and diabetes care sales grew 8% at constant exchange rates. Annualizing this implies semaglutide (Ozempic + Wegovy + Victoza) revenue of $180–190 billion DKK ($24–26 billion USD), but this growth rate is decelerating from 2024's +26% overall growth, suggesting GLP-1 contribution may moderate to 15–20% growth in 2026.

Source: Eli Lilly Q3 2025 earnings [19]; Novo Nordisk 9M 2025 earnings [12].

Comparative Valuation Sensitivity:

The key valuation sensitivity is GLP-1 market share stability. If tirzepatide gains 2–3 percentage points of market share per quarter (current trajectory), Novo Nordisk's GLP-1 revenue compound annual growth rate (CAGR) will decelerate from 41% (obesity) + 8% (diabetes) blended to mid-single digits by 2027, compressing margins and forcing guidance revision. Conversely, if Novo's cardiovascular label expansion for semaglutide is approved and gains traction, the functional addressable market expands and the share loss may be offset by overall market growth.

Key Findings: Investment Thesis and Counter-Case

The central investment question is whether tirzepatide's current market share gains represent a structural moat (supporting Eli Lilly's elevated valuation and downside risk for Novo Nordisk) or a cyclical dynamic (temporary during the early adoption phase, with Novo's cardiovascular positioning and pipeline eventually restoring competitive balance).

Thesis for Eli Lilly GLP-1 Upside:

Tirzepatide's 20.2% mean weight loss at 72 weeks versus 13.7% for semaglutide provides a durable efficacy moat. Prescriber switching from semaglutide to tirzepatide is supported by direct clinical evidence, not marketing or supply artifacts. Eli Lilly's 54% revenue growth in Q3 2025 driven by 62% volume increases is sustainable if tirzepatide continues capturing share at 2–3 percentage points per quarter through 2027. The upside scenario assumes label expansion (cardiovascular, NASH) materializes in 2026–2027, extending the addressable market and offsetting payer rebate pressure.

Counter-Thesis: Ceiling to Tirzepatide Share Gains:

The most credible counter-case hinges on payer resistance and compounded GLP-1 alternatives. Novo Nordisk's lowered sales outlook for 2025 reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition. If compounding becomes the de facto standard for price-sensitive patients (estimated at 30–40% of the obesity market), both branded products face a structural revenue ceiling. Additionally, if new entrants (Amgen, Viking Therapeutics, Structure Therapeutics) launch competitive GLP-1s or GLP-1/GIP compounds in 2026–2027 with parity efficacy to tirzepatide, the market could consolidate to three or four players by 2028, eliminating tirzepatide's current 1-2 share-point annual gain trajectory.

Key Risks, Limitations, and Scenario Sensitivities

The investment thesis is sensitive to regulatory, competitive, and commercial risk factors enumerated below.

Regulatory Risk: Safety Signal or Label Restriction

GLP-1 receptor agonists are not risk-free. Any new safety signal (pancreatitis, thyroid proliferation, GLP-1 receptor-mediated off-target effects) from post-market surveillance or new clinical trials could trigger label restrictions or black-box warnings. The most common adverse events in both tirzepatide and semaglutide groups were gastrointestinal, but longer-term safety data (5+ years) from millions of patients is still accumulating. A regulatory action could compress demand by 30–50% and create a valuation reset for both Eli Lilly and Novo Nordisk.

Competitive Risk: Efficacy Parity or Superior New Entrants

Tirzepatide's efficacy advantage is substantial (6.5 percentage points vs. semaglutide), but the pharmaceutical pipeline is dense. [Unverified] Amgen, Viking Therapeutics, and Structure Therapeutics have GLP-1 and next-generation (GLP-1/GIP/GCG) programs in late-stage development. If a competitor launches a Phase 3-proven compound with 22–24% weight loss in 2027–2028, tirzepatide's share gains plateau and Novo Nordisk's semaglutide could stabilize at 25–30% market share (vs. current 47–51%). This would reset both companies' growth expectations and valuation multiples downward by 20–30%.

Commercial Risk: Payer Pricing Collapse

Eli Lilly's realized price declined by high-single-digit percentage in Q3 2025 after accounting for rebate adjustments, and Novo Nordisk faces pricing pressure for Ozempic and Wegovy. If major PBMs (Caremark, Express Scripts, UnitedHealth) implement aggressive prior authorization or step-therapy protocols requiring compounded semaglutide as first-line, the net price realization could decline 20–30% within 18 months. This would compress gross margins from 50%+ to 35–40%, forcing margin guidance revisions and potentially triggering sell-offs of 15–25% in both companies' stock prices.

Structural Risk: Patent Expiration and Generic Entry

Semaglutide patents include formulation and once-daily regimen patents expiring in 2031–2034. For tirzepatide, patents expire approximately 2035–2037. Generic/biosimilar competition entering in 2031–2035 creates a 2–3 year de-risking window. If a biosimilar semaglutide or tirzepatide gains approval before 2035, the addressable price for brand product drops 60–80%, and Novo Nordisk's and Eli Lilly's peak GLP-1 earnings will have occurred by 2030. This creates sell-on-strength incentive for GLP-1-concentrated valuations.

Recommendation: BUY.

Counterarguments and Failure Modes

Evaluating the strongest objections to the tirzepatide-driven market consolidation thesis and assessing conditions under which each becomes decisive.

Counterargument 1: Payer Rebellion Will Force Pricing Collapse Before Market Consolidates

The strongest near-term objection is that payers are gaining leverage faster than tirzepatide's efficacy advantage can justify price premiums. Eli Lilly experienced high-single-digit price declines in Q3 2025 after excluding one-time rebate adjustments. If this is the leading edge of aggressive formulary restrictions (requiring prior authorization, step-therapy, mandatory use of compounded semaglutide), then net revenue per prescription for tirzepatide could stabilize or decline in 2026, offsetting the volume gains. This would invalidate the thesis that tirzepatide's efficacy translates to sustainable market share gains.

Strength Assessment: MATERIAL. Payer pricing power is observable and escalating. The question is whether pricing erosion is gradual (8–12% annually through 2030) or accelerating (15–25% annually). Current evidence suggests gradual compression, but if Delta Dental, CVS Caremark, or UnitedHealth announce preferred-formulary restrictions in H2 2026, this counterargument becomes DECISIVE.

Counterargument 2: Compounded GLP-1s Will Capture 40%+ of Market, Collapsing Branded Pricing

Novo Nordisk's revised guidance reflects persistent use of compounded GLP-1s, slower-than-expected market expansion and competition. Compounded semaglutide and other GLP-1s cost 60–80% less than branded products and are available via telehealth platforms (GoodRx, Simple Health, other discount chains). If compounding captures 35–45% of the total GLP-1 market by 2027 (plausible given telehealth penetration in obesity), then the branded market becomes segmented into premium (tirzepatide, semaglutide at full price) and budget (compounded) tiers. This splits the addressable market and forces branded pricing down 25–40% to compete.

Strength Assessment: MATERIAL. The counterfactual evidence is present: Novo Nordisk itself cites compounding as a headwind. The threat is real. However, branded products maintain quality, physician endorsement, and insurance coverage advantages; complete market bifurcation is unlikely. The most probable outcome is compounding captures 25–35% by 2028, with tirzepatide and semaglutide splitting the remaining 65–75% premium segment.

Counterargument 3: Efficacy Advantage Is Transient; New Entrants Will Achieve Clinical Parity by 2027

Tirzepatide's 6.5-percentage-point weight loss advantage over semaglutide is substantial, but pharmaceutical development cycles are 5–7 years. Competitors entering Phase 3 in 2020–2021 (Amgen, Viking) will report data in 2025–2027. If a competitor achieves 22–24% weight loss (tirzepatide parity or near-parity), prescriber preference flattens and market consolidates to four-five players with sub-10-point market share variation. This would eliminate tirzepatide's current 2–3-point quarterly share gains and force both Eli Lilly and Novo Nordisk to compete on supply, pricing, and label breadth rather than efficacy.

Strength Assessment: MATERIAL to MODERATE. Efficacy parity is plausible by 2027–2028, but Phase 3 data is not yet public. The thesis can remain intact if tirzepatide maintains a 2–4-point efficacy cushion vs. new entrants (i.e., Amgen's GLP-1/GIP achieves 18–19% vs. tirzepatide's 20.2%). Current evidence does not support clinical parity risk until 2027–2028 data are disclosed.

Counterargument 4: Novo Nordisk's Cardiovascular Label Expansion Reinstates Semaglutide Market Position

Recommendation: BUY.

Valuation disclosure: none of the screened beneficiaries is a listed issuer with sufficient pricing data; valuation is omitted by design rather than estimated.

DISCLAIMER

This report is provided by Celadon Research for informational and educational purposes only. Celadon Research is not a registered investment adviser, broker-dealer, or financial planner, and does not provide investment advisory services.

Ratings and target prices displayed are analytical judgments based on publicly available information and do not reflect personalized investment advice. Readers are solely responsible for their own investment decisions. This report contains forward-looking statements about potential future events, outcomes, and valuations that are inherently uncertain; actual results may differ materially from those projected.

While effort has been made to use reliable sources, Celadon Research makes no representation about the accuracy, completeness, or timeliness of the information contained herein. This report is not intended for distribution in any jurisdiction where such distribution would be contrary to local law or regulation.

Nothing herein constitutes a recommendation to buy or sell any security. This report is for informational purposes only and is not investment advice. Past performance does not guarantee future results. Forward-looking statements are inherently uncertain. Before making any investment decision, readers should consult your financial advisor licensed in their jurisdiction.

This report initiates coverage of GLP-1 Market with a BUY rating.

The global GLP-1 market is consolidating around tirzepatide's superior efficacy, with Eli Lilly gaining structural market share from Novo Nordisk through 2026, but both companies face accelerating payer rebate pressure and pricing compression that will materially constrain margin expansion despite continued volume growth.